解放日报讯 按照市委统一部署，市委副书记朱忠明昨天走访服务重点企业，与企业负责人座谈交 流，面对面了解发展需求，认真听取意见建议，现场回应企业关切。 在中国远洋海运集团有限公司，市领导一行了解企业建设全球数字化供应链、发展绿色低碳航运等 情况，对企业长期以来为上海经济社会发展作出的贡献表示感谢。朱忠明说，上海深入贯彻党的二十届 四中全会和习近平总书记考察上海重要讲话精神，把优化营商环境摆在推动高质量发展的突出位置。希 望企业深耕主责主业，深化创新转型，积极服务企业走出去，携手推进国家战略落实落地。 在罗氏诊断产品（上海）有限公司，市领导一行了解企业在华发展、核心产品等情况，询问企业对 业务创新有何规划、对上海优化营商环境有什么建议。朱忠明表示，上海全力打造世界级生物医药产业 集群，希望企业坚定信心、创新突破，充分用好上海多重优势，把更多新技术、新产品放在上海。相关 部门和区要进一步主动服务企业，对接企业业务布局拓展，推动更多高附加值产品在沪研发生产。 ...

每经AI快讯，南模生物2月27日晚间发布公告称，公司的全资子公司上海砥石生物科技有限公司（以下 简称"砥石生物"）于近日收到了国家重大专项的首笔科研经费113.93万元，其中78.22万元需划拨至其他 参研单位。砥石生物本次获得的科研经费为35.71万元，属于与收益相关的政府补助，占公司最近一个 会计年度经审计净利润的比例为5.50%。 根据《国家科技重大专项课题任务书》，砥石生物预计累计可获得科研经费415.24万元，均为与收益相 关的政府补助，占公司最近一个会计年度经审计净利润的比例为63.93%。 每经头条（nbdtoutiao）——中美大反转，中国AI调用量首超美国，A股嗨了，多板块掀涨停潮！华尔 街知名分析师：中国算力路径颠覆传统认知 （记者 王晓波） ...

在数字经济领域，围绕算力、数据、安全、信创等关键环节，推动资源共享与场景共建；清单显示，位 于经开区的北京国际算力服务有限公司提出，期望与三地医疗、金融、自动驾驶等具备大批量数据的企 业携手进行高质量数据集的开发，为数据交易过程中的合规问题保驾护航，共同促进数据交易行业发 展。统信软件公司提出，希望加强软硬件生态共建，建立三地互认的认证体系，减少重复测试成本。 在现代物流领域，聚焦多式联运、冷链仓储、供应链金融等方向，打造高效畅通的区域物流网络。例 如，北京顺丰速运希望对接出海国际客户资源，并可为河北、天津的汽车企业提供供应链服务解决方 案。 "以前企业找合作，往往是'瞎子摸象'，现在清单在手，方向清晰多了。"一名参与清单编制的企业代表 表示。此次清单的发布，是京津冀三地自贸试验区在深入调研企业实际需求基础上，推动供需精准匹配 的一次创新实践。通过系统梳理企业在产供链建设中的优势与缺口，帮助上下游企业快速找到"对的 人"，打通内外贸一体化路径，拓展全球合作网络。 北京市商务局相关负责人表示，下一步，京津冀三地自贸试验区将围绕全产业链协同创新，持续搭建对 接交流平台，推动技术联合攻关、科技资源开放共享、应用场景 ...

（文章来源：证券日报） 证券日报网讯 2月26日，和元生物发布2025年度业绩快报公告称，公司2025年实现营业总收入26766.34 万元，同比增长7.86%；归属于母公司所有者的净利润为-22071.57万元。 ...

本报记者 柴嵘 "渐冻人""瓷娃娃""蝴蝶宝贝"，这些"美丽"名字的背后，分别对应着肌萎缩侧索硬化症、成骨不全症、大疱性表皮松解症。这些疾病被统称为罕见病，世界 卫生组织将其定义为患病人数占总人口0.065%至0.1%之间的疾病。 每个周四，北京协和医院疑难罕见病会诊中心，来自神经科、儿科、遗传咨询室、放射科等十余个科室的顶尖专家围坐一堂，讨论病情、分析病历。他们研 判的可能是一种全球仅报告过几十例的罕见病，也可能是一个让家庭跑遍全国、花了十多年仍无解的医学难题。 "健康中国的路上，一个都不能少。" 这是北京协和医院院长张抒扬常说的一句话，也是她和团队十多年来的工作信条。面对这片医学的"无人区"，他们正努力搭建一套从诊断到治疗、从医院到 全国的系统，为那些生命孤岛点亮一盏灯。 2025年2月27日，第281场罕见病多学科会诊举行。 1 编织协作网 长期以来，诊断难、治疗难、用药难像三座大山，横亘在罕见病患者面前。先得到一个明确诊断，对许多人来说都是一种奢望。罕见病患者症状复杂，常涉 及多个学科，而具备诊断经验和能力的医生太少。 "医生，我的孩子到底得了什么病？"这样的问题，张抒扬听过太多遍，她感慨："过去有个 ...

Group 1 - The Hubei Provincial Federation of Trade Unions has announced a list of 60 outstanding skilled talents from the industrial frontlines to be trained as "Jingchu Craftsmen" by 2025 [1] - The selected candidates come from key industries such as large equipment manufacturing, new energy and materials research, engineering construction, biomedicine, military precision manufacturing, and cybersecurity management, as well as traditional industries like intangible cultural heritage [1] - The training program focuses on a dual emphasis on morality and skills, aiming to enhance the "Five Powers of Craftsmen"—leadership, achievement, innovation, focus, and inheritance, with a two-year training period designed to make them core forces in technological transformation, equipment updates, and industrial upgrades [1] Group 2 - The training will be conducted in three phases: "Cultivating Craftsmanship, Enhancing Skills, and Developing Talents," utilizing workshops, cultural immersion, and ideological education to strengthen spiritual guidance and personal development [2] - Resources such as model craftsmen innovation studios and craft academies will be leveraged to improve skills and innovation capabilities through platform empowerment, special projects, and technical training [2] - Upon completion of the training, approximately 50 "Jingchu Craftsmen" will be certified, with a goal to inspire and train around 500 additional craftsmen at the municipal or enterprise level [2]

Group 1 - Beijing Rural Commercial Bank's Economic and Technological Development Zone Branch issued its first "Technology R&D Loan" of over 2.36 million yuan to Beijing Huanuo Tai Biopharmaceutical Technology Co., Ltd., providing crucial funding for vaccine innovation and R&D [1] - The loan will specifically support key aspects of vaccine R&D, including raw material procurement, laboratory equipment upgrades, and team support, addressing the financing challenges faced by biopharmaceutical companies due to a lack of collateral [1][2] - The innovative financing model transforms the company's R&D investment, core patents, and team qualifications into credit assessment criteria, allowing for more flexible financing solutions for technology-driven enterprises lacking tangible assets [2] Group 2 - The "Technology R&D Loan" is part of a broader financial service system aimed at supporting technology innovation, with Beijing Rural Commercial Bank offering a product matrix of 75 financial products covering the entire lifecycle of enterprises [3] - This initiative reflects the bank's commitment to addressing the financing difficulties of biopharmaceutical companies and supporting the real economy and technological innovation [3] - The bank plans to deepen its technological financial innovation practices and enhance its credit product offerings, contributing to the construction of an international technology innovation center in Beijing and the high-quality development of the real economy [3]

Core Viewpoint - The company, 英矽智能 (03696), has been selected to be included in the Hang Seng Composite Index, effective from March 9, 2026, which reflects strong recognition from the international capital market regarding its industry position, business performance, and value [1] Group 1 - The inclusion in the Hang Seng Composite Index is expected to enhance the liquidity of the company's shares [1] - This move is anticipated to diversify the shareholder structure and expand the investor base [1] - The company believes that this development will promote its long-term growth [1]

Core Viewpoint - Zhejiang University published a paper titled "De novo Design of GPCR Exoframe Modulators" in Nature, showcasing the practical capabilities of artificial intelligence in membrane protein design and functional reconstruction, providing a new technical pathway for understanding and utilizing the regulatory potential of G protein-coupled receptor exoframe modulators (GEM) [1][3]. Group 1 - The research team, led by interdisciplinary doctoral student Cheng Shizhuo, includes members from Zhejiang University School of Medicine and the School of Computer Science, indicating a collaborative approach to tackle GPCR-related challenges [3][5]. - GPCRs, as the largest "signal receivers" in the human body, are crucial for regulating key life processes such as sensation, emotion, cardiovascular function, and metabolism [3][5]. - The study proposes an "exoskeleton" approach to receptor regulation, where GEM acts on the transmembrane domain of GPCRs, altering their conformational state to finely tune signal output, differing from traditional drugs that occupy receptor pockets [5][6]. Group 2 - The research team discovered that the AI-designed GEM modules can be fused with GPCRs, expanding the classic seven transmembrane helices to nine or even thirteen, thereby regulating downstream signaling pathways and their corresponding functions [5][6]. - The interdisciplinary training of Cheng Shizhuo involves attending multiple group meetings weekly to integrate medical knowledge and computer skills, transforming biological genetic codes into logical computational languages [5][6]. - The team aims to provide new therapeutic strategies for GPCR functional disorders, such as certain Parkinson-like syndromes, which have long lacked effective intervention methods [8].

Core Viewpoint - The article discusses a groundbreaking study on GPCR (G-protein-coupled receptor) modulation through the introduction of a novel concept called "GPCR Exoframe Modulators" (GEM), which utilizes deep learning for the design of proteins that target GPCR transmembrane domains, offering new therapeutic avenues for GPCR-related diseases [2][3][4]. Group 1 - GPCR is the largest membrane protein family in the human body, responsible for transducing various extracellular signals and regulating a wide range of physiological processes, making it a primary drug target [2]. - The research team from Zhejiang University published their findings in Nature, introducing the concept of GEM, which can specifically bind to the transmembrane surface of GPCRs and stabilize specific receptor conformations [3][4]. - The study highlights the potential of deep learning methods in designing function-oriented membrane proteins, marking a significant advancement in GPCR allosteric modulation [8]. Group 2 - The research focused on the dopamine D1 receptor (D1R) as a prototype model, investigating four types of GEM: GEM anchor, GEM BAM, GEM NAM, and GEM ago-PAM, which exhibit various allosteric modulation functions [6]. - Among these, GEM ago-PAM has shown the ability to restore the activity of multiple D1R loss-of-function mutants, providing a new potential target for the treatment of GPCR-related diseases [6][8]. - The study emphasizes that targeting transmembrane domains with GEM can serve as an effective tool for GPCR allosteric modulation, showcasing the innovative approach to drug design [8].